Radioimmunoconjugates in Renal Cell Carcinoma

  • R. L. Vessella


The long-awaited clinical benefits of radioimmunoscintigraphy (RIS) and radioimmunotherapy (RIT) are being realized in a slow but steadily progressive fashion [1]. The visualization of tumor foci no longer requires extensive manipulative steps to discriminate uptake of radiolabeled antibody by the tumor from that of the blood pool or normal tissues, and in therapeutic regimens significant tumor responses are becoming more common. However, the past decade of animal studies and clinical efforts utilizing radionuclide conjugated monoclonal antibodies (MAb) has demonstrated the vast complexities of the task at hand, and even as enthusiasm is growing, significant hurdles remain to be cleared if RIS and RIT are to achieve their anticipated clinical potential. We have been actively exploring the use of RIS and RIT in renal cell carcinoma (RCC) xenografts for 5 years and in clinical trials for approximately 2 years. This report will briefly review the progress to date and then in more detail will provide an overview of the key RIS and RIT issues that are being addressed by the scientific community.


Renal Cell Carcinoma Human Renal Cell Carcinoma Mass Dose Human Anti Mouse Antibody Human Renal Cell Cancer 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Larson SM (1990) Clinical radioimmunodetaction, overview and suggestions for standardization of clinical trials. Cancer Res 50 (Suppl): 892–898Google Scholar
  2. 2.
    Dayman RV, Figenshau RS, Bear A, Limas C (1985) Transplantation of human renal cell carcinoma into athymic mice. Cancer Res 45: 2650–2653Google Scholar
  3. 3.
    Williams RD, Elliot AY, Stein N, etal. (1978) In vitro cultivation of human renal cell cancer. In Vitro 14: 779–786Google Scholar
  4. 4.
    Vessella R, Moon T, Chiou R, Nowak J, Arfman E, Palme D, Peterson G, Lange P (1985) Monoclonal antibodies to human renal cell carcinoma: Recognition of shared and restricted antigens. Cancer Res 45: 6131–6139PubMedGoogle Scholar
  5. 5.
    Chiou RK, Vessella RL, Elson MK, Dayman RV, Gonzalez-Campoy J, Klicka MJ, Shafer RB, Lange PH (1985) Localization of human renal cell carcinoma xenografts with a tumor-preferential monoclonal antibody. Cancer Res 45: 6140–6146PubMedGoogle Scholar
  6. 6.
    Moon T, Vessella R, Palme D, Nowak J, Lange P (1985) A highly restricted antigen for renal cell carcinoma defined by a monoclonal antibody. Hybridoma 4: 163–171PubMedCrossRefGoogle Scholar
  7. 7.
    Vessella RL, Lange PH, Palme DF, Chiou RK, Elson MK, Wessels BW (1988) Radioiodinated monoclonal antibodies in the imaging and treatment of human renal cell carcinoma xenografts in nude mice. In: Rodwell JD (ed) Antibody-mediated delivery systems. Dekker, New York, pp 245–282Google Scholar
  8. 8.
    Vessella R, Alvarez V, Chiou R, Rodwell J, Elson M, Palme D, Shafer R, Lange P (1987) Radioimmunoscintigraphy and radioimmunotherapy of renal cell carcinoma xenografts. NCI Monographs 3: 159–167PubMedGoogle Scholar
  9. 9.
    Wessels VW, Vessella RL, Palme DF, Berkopec JM, Smith GK, Bradley EW (1989) Radiobiological comparison of external beam irradiation and radioimmunotherapy in renal cell carcinoma xenografts. Int J Radiotion Oncology Biol Phys 17: 1257–1263CrossRefGoogle Scholar
  10. 10.
    Wessels BW (1990) Current status of animal radioimmunotherapy. Cancer Res 50 (Suppl): 970s–973sPubMedGoogle Scholar
  11. 11.
    Langmuir VK, Sutherland RM (1988) Radiobiology of radioimmunotherapy: Current status. Antibody Immunocon Radiophar 1 (3): 195–211Google Scholar
  12. 12.
    Humm JL, Cobb LM (1990) Nonuniformity of tumor dose in radioimmunotherapy. J Nucl Med 31: 75–83PubMedGoogle Scholar
  13. 13.
    Berkopec JM, Bradley BW, Wessels DF, Palme DF, Montilla L, Vessella RL (1989) Combined external beam irradiation (XRT) and radioimmunotherapy (RTT) on renal cell carcinoma xenografts. J Nucl Med 30 (5): 406Google Scholar
  14. 14.
    Vessella RL, Chiou RK, Grund FM, Elson MK, Johnson TK, Nowak JA, Palme DF, Lightner DJ, Mathisen ML, Wessels BW, Olson RE, Rittenhouse HG, Stroup SD, Lange PH (1987) Renal cell carcinoma (RCC) phase I–II trials with 131-I labeled monoclonal antibody A6H: Imaging and pharmacokinetic studies. Proc Am Assoc Cancer Res 28: 1525Google Scholar
  15. 15.
    Lightner DJ, Vessella RL, Chiour RK, Grand FM, Johnson TK, Elson MK, Wessels BW, Stroupe SD, Mathisen ML, Lange PH (1988) Renal cell carcinoma phase I–II trials with 1–131 monoclonal antibody (MoAb) A6H. Proc Third International Conference on Monoclonal Antibody Immunoconjugates for Cancer, vol 92, p 119Google Scholar
  16. 16.
    Wessels VW, Rogus RP (1984) Radionuclide selection and model absorbed dose calculations for radiolabeled tumor associated antibodies. Med Phys 11: 638–645PubMedCrossRefGoogle Scholar
  17. 17.
    Griffin TW, Collins J, Bokhari F, Stochl M, Brill AB, Ito T, Emond G, Sands H (1990) Intraperitoneal immunoconjugates. Cancer Res 50 (Suppl): 103ls–1038sGoogle Scholar
  18. 18.
    Sands H (1990) Experimental studies of radioimmunodetection of cancer: An overview. Cancer Res 50 (Suppl): 809s–813sPubMedGoogle Scholar
  19. 19.
    Jain RK (1990) Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res 50 (Suppl): 814s–819sPubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • R. L. Vessella
    • 1
  1. 1.Department of Urology RL-10University of Washington Medical CenterSeattleUSA

Personalised recommendations